Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism

about

Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism

Item

http://www.wikidata.org/entity/Q35920702

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Variable Resistance to Plasmin ...... ediate-Risk Pulmonary Embolism

@ast

Variable Resistance to Plasmin ...... ediate-Risk Pulmonary Embolism

@en

type

Item

label

Variable Resistance to Plasmin ...... ediate-Risk Pulmonary Embolism

@ast

Variable Resistance to Plasmin ...... ediate-Risk Pulmonary Embolism

@en

prefLabel

Variable Resistance to Plasmin ...... ediate-Risk Pulmonary Embolism

@ast

Variable Resistance to Plasmin ...... ediate-Risk Pulmonary Embolism

@en

P1476

Variable Resistance to Plasmin ...... ediate-Risk Pulmonary Embolism

@en

P2093

Jeffrey A Kline

http://www.w3.org/2001/XMLSchema#string

Matthew T Rondina

http://www.w3.org/2001/XMLSchema#string

William B Stubblefield

http://www.w3.org/2001/XMLSchema#string

P2860

Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease

Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis

Acquired defects of fibrinolysis associated with thrombosis.

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.

ATS statement: guidelines for the six-minute walk test.

Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents.

Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a meta-analysis.

Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study.

Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis.

A faster-acting and more potent form of tissue plasminogen activator.

P304

e0148747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0148747

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nathan J Alves

P577

2016-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26866684

http://www.w3.org/2001/XMLSchema#string

P932

4751085

http://www.w3.org/2001/XMLSchema#string